New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway

2017/04/29 by Zhi-Han Tang, Zhi‐Han Tang, Juan Peng +16 · 26 citations
Medicine · Immunology and Microbiology · #Lipoproteins and Cardiovascular Health #Cholesterol and Lipid Metabolism #Atherosclerosis and Cardiovascular Diseases

paper · doi:10.1016/j.atherosclerosis.2017.04.023

Cited by

• Are we underestimating the benefits of lipid-lowering therapies?
• PCSK9 induces a pro-inflammatory response in macrophages. [europepmc]
• Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials. [europepmc]
• Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. [europepmc]
• Exosomal miR-451 from human umbilical cord mesenchymal stem cells attenuates burn-induced acute lung injury. [europepmc]
• Metabolic Syndrome and Skin Diseases. [europepmc]
• Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes. [europepmc]
• An Update on the Role of PCSK9 in Atherosclerosis. [europepmc]
• PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation. [europepmc]
• Pleiotropic Effects of PCSK-9 Inhibitors. [europepmc]
• PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation. [europepmc]
• PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology. [europepmc]
• Regulation of PCSK9 Expression and Function: Mechanisms and Therapeutic Implications. [europepmc]
• PCSK9 Induces Tissue Factor Expression by Activation of TLR4/NFkB Signaling. [europepmc]
• Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis. [europepmc]
• Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review. [europepmc]
• The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. [europepmc]
• The Multifaceted Biology of PCSK9. [europepmc]
• PCSK9 Inhibition: From Current Advances to Evolving Future. [europepmc]
• Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Promotes Macrophage Activation via LDL Receptor-Independent Mechanisms. [europepmc]
• The evolving landscape of PCSK9 inhibition in cancer. [europepmc]
• Regulation of toll-like receptor (TLR) signaling pathways in atherosclerosis: from mechanisms to targeted therapeutics. [europepmc]
• Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. [europepmc]
• Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. [europepmc]
• Vascular leak in sepsis: physiological basis and potential therapeutic advances. [europepmc]
• PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor. [europepmc]